MedKoo Cat#: 575413 | Name: Fepradinol oxalate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fepradinol is an antirheumatic and anti-inflammatory agent. Fepradinol inhibited the early and late stages of concanavalin A-induced edema in rats. Fepradinol prevented the carrageenin-induced inflammation in rats. Fepradinol prevented diarrhoea induced by intravenous injection of endotoxin in mice or by oral administration of castor oil in rats.

Chemical Structure

Fepradinol oxalate
Fepradinol oxalate
CAS#1185076-47-4 (oxalate)

Theoretical Analysis

MedKoo Cat#: 575413

Name: Fepradinol oxalate

CAS#: 1185076-47-4 (oxalate)

Chemical Formula: C12H19NO2

Exact Mass: 209.1416

Molecular Weight: 209.29

Elemental Analysis: C, 68.87; H, 9.15; N, 6.69; O, 15.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Synonym
Fepradinol; G 131; G131; G-131
IUPAC/Chemical Name
Benzenemethanol, alpha-(((1,1-dimethyl-2-hydroxyethyl)amino)methyl)-
InChi Key
PVOOBRUZWPQOER-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H19NO2/c1-12(2,9-14)13-8-11(15)10-6-4-3-5-7-10/h3-7,11,13-15H,8-9H2,1-2H3
SMILES Code
CC(C)(CO)NCC(O)c1ccccc1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 209.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Barranco R, Rodríguez A, de Barrio M, Trujillo MJ, de Frutos C, Matheu V, Tornero P, Herrero T. Sympathomimetic drug allergy: cross-reactivity study by patch test. Am J Clin Dermatol. 2004;5(5):351-5. doi: 10.2165/00128071-200405050-00008. PMID: 15554736. 2: Santos-Briz A, Antúnez P, Muñoz E, Morán M, Fernández E, Unamuno P. Vascular- occlusive contact dermatitis from fepradinol. Contact Dermatitis. 2004 Jan;50(1):44-6. doi: 10.1111/j.0105-1873.2004.00271e.x. PMID: 15059106. 3: Rodríguez Granados T, Piñeiro G, de la Torre C, Cruces Prado MJ. Photoallergic contact dermatitis from fepradinol. Contact Dermatitis. 1998 Oct;39(4):194-5. doi: 10.1111/j.1600-0536.1998.tb05895.x. PMID: 9817228. 4: Goday JJ, Yanguas I, González-Güemes M, Oleaga JM, Ilardia R, Soloeta R. No evidence of cross-reaction between fepradinol and other phenylethanolamines. Contact Dermatitis. 1997 Mar;36(3):170-1. doi: 10.1111/j.1600-0536.1997.tb00410.x. PMID: 9145277. 5: Gonzalo MA, Revenga F. Multiple cutaneous sensitization to nonsteroidal anti- inflammatory drugs. Dermatology. 1996;193(1):59-60. doi: 10.1159/000246205. PMID: 8864624. 6: Masso JM, Villar AM, Conde JR, Martorell J. Effects of fepradinol on rat acute models of vascular permeability and leucocyte migration. Agents Actions. 1994 Oct;42(3-4):118-22. doi: 10.1007/BF01983476. PMID: 7879696. 7: Ortiz-Frutos FJ, Hergueta JP, Quintana I, Zarco C, Iglesias L. Allergic contact dermatitis from fepradinol: report of 4 cases and review of the literature. Contact Dermatitis. 1994 Sep;31(3):193-5. doi: 10.1111/j.1600-0536.1994.tb01971.x. PMID: 7821022. 8: Aranzabal A, De Barrio M, Rodriguez V, Baeza ML, Tornero P. Allergic contact dermatitis from fepradinol. Contact Dermatitis. 1994 Aug;31(2):121. doi: 10.1111/j.1600-0536.1994.tb01935.x. PMID: 7750256. 9: Schnuch A. Fepradinol allergy: possibly a case of unnoticed cross-reaction due to misclassification. Contact Dermatitis. 1994 Apr;30(4):243-5. doi: 10.1111/j.1600-0536.1994.tb00656.x. PMID: 8033556. 10: Gomez A, Martorell A, de la Cuadra J. Allergic contact dermatitis from fepradinol in a child. Contact Dermatitis. 1994 Jan;30(1):44. doi: 10.1111/j.1600-0536.1994.tb00730.x. PMID: 8156765. 11: Massó JM, Villar AM, Conde JR, Martorell J. Mechanism of anti-inflammatory action of fepradinol. Arzneimittelforschung. 1994 Jan;44(1):68-74. PMID: 7907874. 12: Masso JM, Conde JR, Villar AM, Martorell J. Effect of fepradinol on rat hind paw oedema induced by several inflammatory agents. J Pharm Pharmacol. 1993 Nov;45(11):959-62. doi: 10.1111/j.2042-7158.1993.tb05635.x. PMID: 7511161. 13: Goday JJ, Yanguas I, Ilardia R, Soloeta R. Subacute contact dermatitis from fepradinol. Contact Dermatitis. 1993 Sep;29(3):160. doi: 10.1111/j.1600-0536.1993.tb03521.x. PMID: 8222635. 14: Izu R, Aguirre A, Irazabal B, Goday J, Díaz-Pérez JL. Allergic contact dermatitis from fepradinol. Contact Dermatitis. 1992 Oct;27(4):266-7. doi: 10.1111/j.1600-0536.1992.tb03267.x. PMID: 1451503. 15: Waldeck B, Jeppsson AB, Widmark E. Partial agonism and functional selectivity: a study on beta-adrenoceptor mediated effects in tracheal, cardiac and skeletal muscle. Acta Pharmacol Toxicol (Copenh). 1986 Mar;58(3):209-18. doi: 10.1111/j.1600-0773.1986.tb00096.x. PMID: 2872766.